BPC-157 dosing, reconstitution, and storage are among the most-searched practical questions in peptide research — and also among the least standardized, since no single dose, delivery form, or handling protocol for BPC-157 has been formally validated in controlled human trials. This guide walks through what the published literature actually documents for both injectable and capsule forms of BPC-157, where the real gaps in the science are, and how TelosRX's licensed providers make the individualized calls that population-level research alone can't.
Why BPC-157's Chemistry Matters for Dosing and Storage
BPC-157 (GEPPPGKPADDAGLV) is a synthetic 15-amino-acid peptide, roughly 1,419 daltons, derived from a sequence identified in human gastric juice. A 2026 biopharmaceutical review published in Pharmaceutics — one of the few papers to evaluate BPC-157 specifically from a formulation and drug-development standpoint — describes its physicochemical profile in detail, and the picture it paints is directly relevant to how the peptide is handled outside the body, not just inside it.
A few structural facts from that review explain why reconstitution and storage instructions exist at all:
- Gastric stability: BPC-157's N-terminal polyproline cluster forms a rigid, protease-resistant structure, which is why it remains detectable in human gastric juice even after prolonged exposure to pepsin and stomach acid — the physiological basis researchers cite for studying an oral (capsule) form at all.
- Hydrolysis risk: The Asp10–Asp11 junction in the sequence is flagged as the peptide's principal site of hydrolytic and succinimide-formation risk under acidic or neutral conditions — a chemistry detail that underlies why reconstituted peptide solutions are handled cold and used within a defined window rather than left at room temperature indefinitely.
- Glycation liability: The single lysine residue in the sequence can react with reducing sugars sometimes used as bulking agents in lyophilized peptide products, which is why compounding formulations favor non-reducing alternatives like trehalose or mannitol.
- Rapid clearance: Confirmed pharmacokinetic data — both in animal models and in a small human pilot — puts BPC-157's plasma half-life at under 30 minutes, even though its downstream biological effects are studied over a period of hours to days.
The same review is candid about a limitation worth stating plainly: no pharmaceutical-grade formulation of BPC-157 has been developed or formally validated, and no forced-degradation or shelf-life study specific to reconstituted BPC-157 solutions has been published. That doesn't mean handling instructions are arbitrary — they're extrapolated from general peptide chemistry and the compound's known degradation risks — but it does mean patients should follow the specific instructions and beyond-use date provided by their dispensing pharmacy rather than a generic timeline found online.
Preclinical and Early Human Dosing Data
Almost everything known about BPC-157 dosing comes from two very different sources: rodent studies using intraperitoneal injection, and a single small human pilot study.
A 2019 rat study on spinal cord injury, for example, tested doses of 2 μg/kg and 200 μg/kg administered intraperitoneally — a 100-fold range that itself illustrates how unsettled dose-response data still is in animal models. Other published rodent studies have used doses spanning from roughly 10 μg/kg down to the nanogram-per-kilogram range, depending on the injury model and outcome measured.
On the human side, the only published dosing data comes from a 2025 pilot study in Alternative Therapies in Health and Medicine, which examined intravenous BPC-157 in two adults with prior BPC-157 experience: 10 mg on day one and 20 mg on day two, each diluted in saline and infused over an hour. The study reported no adverse effects and no measurable impact on cardiac, hepatic, renal, thyroid, or glucose biomarkers — but a two-person, unblinded pilot cannot establish a safe or effective dose for the general population, and the authors themselves frame it as a starting point for further research, not a protocol.
| Data source | Documented dose | Route | What it does not establish |
|---|---|---|---|
| Perovic et al., 2019 (rat model) | 2–200 μg/kg | Intraperitoneal | Human equivalent dosing; animal-to-human extrapolation is not linear |
| Multiple rodent studies (various models) | ~10 ng/kg – 10 μg/kg | Intraperitoneal or oral (drinking water) | A standardized "effective dose" across conditions |
| Lee & Burgess, 2025 (human pilot, n=2) | 10 mg day 1, 20 mg day 2 | Intravenous infusion | Safety or dosing guidance for subcutaneous/IM injection or oral capsules |
The takeaway isn't a number — it's the gap. Rodent doses are measured in micrograms per kilogram; the one published human study used milligram-scale IV infusions in two people. There is no controlled human dose-ranging study connecting the two, which is precisely why any compounded BPC-157 preparation dispensed through a licensed pharmacy is dosed on an individualized basis by the prescribing provider, not from a published chart.
BPC-157 Injection: Reconstitution as Documented in Compounding Practice
Compounded BPC-157 injection is dispensed as a lyophilized (freeze-dried) peptide that must be reconstituted with bacteriostatic water before use. The math behind reconstitution is straightforward arithmetic, not a clinical claim, but it's worth understanding since it's frequently searched:
| Vial strength (as compounded) | Bacteriostatic water added | Resulting concentration |
|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL |
| 5 mg | 5 mL | 1 mg/mL |
| 10 mg | 2 mL | 5 mg/mL |
| 10 mg | 5 mL | 2 mg/mL |
General peptide-handling convention — not a BPC-157-specific validated protocol — calls for injecting the bacteriostatic water slowly down the inside wall of the vial and swirling gently rather than shaking, since vigorous agitation can denature or aggregate peptide chains. Every vial TelosRX's compounding pharmacy partner dispenses arrives labeled with the exact diluent volume, resulting concentration, and beyond-use date for that specific preparation — those labeled instructions always take precedence over generic figures like the ones above.
Storage: What Changes Before and After Reconstitution
Storage requirements differ meaningfully depending on whether the peptide has been reconstituted:
| Form | Documented handling convention |
|---|---|
| Lyophilized (unreconstituted) vial | Refrigerated or frozen per the pharmacy label; protected from light and moisture |
| Reconstituted injectable solution | Refrigerated (approximately 36–46°F / 2–8°C); protected from light; not refrozen; used within the beyond-use date on the pharmacy label |
| Compounded capsules | Room temperature, tightly sealed, away from heat, light, and humidity, per the pharmacy label |
As noted above, no controlled stability study specific to reconstituted BPC-157 has been published in the peer-reviewed literature — the cold-chain and light-protection conventions above are drawn from the peptide's known chemistry (its hydrolysis and glycation liabilities) and from general compounding-pharmacy practice for peptide products, not from a BPC-157-specific shelf-life trial. The beyond-use date assigned by your dispensing pharmacy — which factors in USP compounding standards — is the number that matters for your specific preparation, not a generic figure from a forum or blog post.
BPC-157 Capsules: Oral Stability and Reported Dosing Timing
The rationale for an oral BPC-157 capsule form rests on that same gastric-stability property described above: unlike most peptides, which are broken down almost immediately by stomach acid and pepsin, BPC-157's polyproline-rich structure allows it to survive that environment intact for an extended period. That's a meaningfully different pharmacological premise than most injectable peptides, and it's the reason BPC-157 is one of relatively few peptides studied — mostly in animal models — as an oral candidate at all.
That said, oral bioavailability and absorption data in humans is considerably thinner than the injectable literature. Practitioners and observational reports commonly describe capsule regimens taken on an empty stomach — often 30 to 60 minutes before a meal — reasoning that food-driven changes in gastric pH and transit time could affect how much intact peptide reaches the intestine for absorption. Some regimens split dosing into a morning and evening capsule rather than a single daily dose, though this pattern reflects practitioner convention documented in observational reports rather than a validated pharmacokinetic protocol.
On "how many capsules per day" — there is no universal answer, because compounded capsule strength varies by pharmacy and by preparation (commonly in the low hundreds-of-micrograms to low-milligram range per capsule). The relevant number for you is the one written on your prescription label, set by your provider after evaluation, not a fixed count from an online chart.
Documented Dosage Ranges: Context, Not a Protocol
Because this is one of the most commonly searched questions about BPC-157, here is a plain summary of what shows up across compounding and observational literature. This table is provided for research context only — it is not a prescriptive protocol, and any actual prescription is an individualized decision made by a licensed provider after clinical evaluation.
| Format | Range referenced in compounding/observational literature | Frequency pattern reported |
|---|---|---|
| Subcutaneous injection | Low hundreds of micrograms to a few milligrams per injection | Once or twice daily, cycles of several weeks, per provider direction |
| Oral capsule | Low hundreds of micrograms to a few milligrams per capsule | One to two capsules daily, timed apart from meals, per provider direction |
These figures describe what appears in the literature and in compounding pharmacy practice — they are not a recommendation, a guarantee of any outcome, or a substitute for individualized dosing set by your prescribing provider.
What About a BPC-157 + TB-500 Blend Dosage Calculator?
Some patients search for a combined BPC-157 + TB-500 "blend" dosage calculator, sometimes referred to informally as the "Wolverine stack." It's important to address this directly: in late 2023, the FDA classified TB-500 (Thymosin Beta-4) as a Category 2 bulk drug substance, which currently prohibits licensed compounding pharmacies from preparing or dispensing TB-500 for human use. That means a validated combined-dose calculator for a BPC-157/TB-500 blend does not exist, and any product marketed as one is not reflecting a currently legally compoundable preparation. This status is subject to change as FDA and Pharmacy Compounding Advisory Committee (PCAC) review continues, but as of this writing it stands. You can read more about TB-500's research background and current regulatory status in our TB-500 tissue repair research overview. BPC-157 alone, by contrast, remains available through licensed compounding pharmacies by prescription, subject to individual provider evaluation.
Safety, FDA Status & Competitive Sport Rules
A few regulatory facts should frame every dosing decision:
- Not FDA-approved. BPC-157 is not an FDA-approved drug for any indication. It is available only as a compounded preparation, prepared by a licensed pharmacy under federal and state compounding regulations, and dispensed only by prescription after evaluation by a licensed provider. Approval is never automatic or guaranteed.
- Human clinical data is limited. As detailed above, controlled human dose-ranging trials do not exist. The bulk of the evidence base is preclinical (animal) research, supplemented by a single small human safety pilot. No specific efficacy outcome or percentage should be inferred from animal data.
- Prohibited for competitive athletes. BPC-157 is listed under the World Anti-Doping Agency (WADA) Prohibited List in the S0 (Non-Approved Substances) category, and USADA explicitly warns athletes that its unapproved status means there is no pathway to a therapeutic use exemption. Athletes subject to WADA/USADA testing — or any organization with similar rules — should not use BPC-157 in any form, injectable or oral, without confirming their sport's current anti-doping rules.
For general background on what BPC-157 is and how it's studied, see our BPC-157 patient guide. If your interest is specifically in tendon or connective tissue recovery research, our guide to peptides studied for tendon repair compares BPC-157 against other options in that category.
How TelosRX Approaches BPC-157 Evaluation
TelosRX is an online-first, asynchronous telehealth service. Rather than publishing a one-size-fits-all protocol, our process is built around individualized evaluation:
- Step 1: Complete an asynchronous intake describing your health history and goals at TelosRX.
- Step 2: A licensed provider reviews your intake and determines clinical appropriateness.
- Step 3: If appropriate, the provider issues a prescription specifying format, strength, and directions — including reconstitution and storage instructions specific to your preparation.
- Step 4: Your compounded preparation — injectable or capsule — ships discreetly, with pharmacy labeling that reflects the exact concentration and beyond-use date for that batch.
Start your private evaluation at TelosRX's BPC-157 injection page or BPC-157 capsule page.
Frequently Asked Questions
What is the typical BPC-157 dosage documented in research?
There is no single documented human dosage. Preclinical rodent studies have used doses ranging from roughly 2 to 200 micrograms per kilogram by intraperitoneal injection, while the only published human pilot study used 10 mg on day one and 20 mg on day two by IV infusion in two subjects. These figures don't translate directly into a human injection or capsule protocol — actual prescriptions are set individually by a licensed provider.
How do you reconstitute BPC-157 for injection?
Compounded BPC-157 injection is typically dispensed as a lyophilized vial that is reconstituted with bacteriostatic water — for example, a 5 mg vial mixed with 2 mL of bacteriostatic water yields roughly 2.5 mg/mL. The water is generally added slowly along the vial wall and mixed with a gentle swirl rather than shaken, since vigorous agitation can damage peptide structure. Always follow the specific reconstitution instructions and diluent volume printed on your pharmacy's label, since concentration and vial size can vary by preparation.
How should reconstituted BPC-157 be stored?
General peptide-handling convention calls for refrigerating reconstituted BPC-157 solution (roughly 36–46°F / 2–8°C), protecting it from light, and avoiding refreezing, using it within the beyond-use date set by the dispensing pharmacy. No formal, peer-reviewed shelf-life study specific to reconstituted BPC-157 has been published, so the specific date on your pharmacy label — not a generic online timeline — should be treated as authoritative.
How many BPC-157 capsules should I take per day?
There is no universal capsule count, because compounded capsule strength varies by pharmacy and preparation. Observational and practitioner reports commonly describe one to two capsules per day, but the number, strength, and timing that apply to you are set by your prescribing provider based on the specific preparation dispensed to you.
When is the best time to take BPC-157 capsules?
Practitioner and observational reports commonly describe taking oral BPC-157 on an empty stomach, roughly 30 to 60 minutes before a meal, on the reasoning that food-related changes in stomach acidity and transit time could affect absorption. Some regimens split dosing into a morning and evening capsule. This reflects commonly reported practice rather than a validated human pharmacokinetic protocol, and your provider's specific directions should take precedence.
Is there a validated dosage calculator for a BPC-157 + TB-500 blend?
No. TB-500 was classified by the FDA in late 2023 as a Category 2 bulk drug substance, which currently prohibits licensed compounding pharmacies from preparing it for human use. Because TB-500 is not currently compoundable, no validated combined dosing calculator exists, and any such tool or product does not reflect a currently available compounded preparation.
Is BPC-157 approved by the FDA, and can athletes use it?
BPC-157 is not FDA-approved for any human use; it is available only as a compounded preparation by prescription after evaluation by a licensed provider. It is also listed on the World Anti-Doping Agency's Prohibited List under the S0 (Non-Approved Substances) category, and USADA has stated there is no therapeutic use exemption pathway for it — athletes subject to anti-doping testing should not use it in any form.
Does reconstitution or capsule form affect how BPC-157 works?
The two formats rest on different premises. Injectable BPC-157 bypasses the digestive tract entirely, while the oral capsule form relies on BPC-157's documented stability in gastric juice to survive digestion largely intact. Human comparative data between the two routes has not been published, so neither format's relative effect can be quantified — a licensed provider can help you weigh which format fits your situation during evaluation.
Ready to have a licensed provider set dosing and handling specific to you? Start a short online visit.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.